Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
Trial details
- Registry ID
- NCT04143217
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as viloxazine extended-release capsules; viloxazine extended-release capsules (Qelbree)
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHDNCT04143217 | SUPN | Phase 3 | Completed | 2022-07-26Actual |
| Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)NCT02736656 | SUPN | Phase 3 | Active not recruiting | 2026-12Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |